ReViral Revenue and Competitors
Estimated Revenue & Valuation
- ReViral's estimated annual revenue is currently $930k per year.
- ReViral's estimated revenue per employee is $155,000
Employee Data
- ReViral has 6 Employees.
- ReViral grew their employee count by 0% last year.
ReViral's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CHIEF EXECUTIVE OFFICER | Reveal Email/Phone |
ReViral Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is ReViral?
ReViral – Innovative therapies for viral diseases ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds. The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion RV521 which has completed its Phase 1 clinical studies and has shown significant activity in phase 2 clinical studies in adult volunteers. RV521 is now moving towards phase 2 studies in infant and adult patients.
keywords:N/A
N/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ReViral News
Pfizer is taking a deeper dive into infectious disease with the acquisition of North Carolina-based ReViral, a privately-held biotech...
ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an...
ReViralwhich has operations in both London and Durham, NChas developed an RSV-focused pipeline led by sisunatovir (formerly RV521), an oral...
Other Companies in Stevenage
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2M | 13 | 0% | N/A |
#2 | $1.4M | 16 | 0% | N/A |
#3 | $2.4M | 24 | N/A | N/A |
#4 | $3.7M | 24 | 9% | $3M |
#5 | $2M | 26 | 63% | N/A |